全文获取类型
收费全文 | 297154篇 |
免费 | 17642篇 |
国内免费 | 415篇 |
专业分类
耳鼻咽喉 | 4258篇 |
儿科学 | 10353篇 |
妇产科学 | 10297篇 |
基础医学 | 45076篇 |
口腔科学 | 7534篇 |
临床医学 | 24257篇 |
内科学 | 56183篇 |
皮肤病学 | 6334篇 |
神经病学 | 21049篇 |
特种医学 | 11655篇 |
外国民族医学 | 43篇 |
外科学 | 46934篇 |
综合类 | 7778篇 |
现状与发展 | 1篇 |
一般理论 | 160篇 |
预防医学 | 19937篇 |
眼科学 | 7043篇 |
药学 | 20903篇 |
中国医学 | 787篇 |
肿瘤学 | 14629篇 |
出版年
2019年 | 2273篇 |
2018年 | 3652篇 |
2017年 | 2679篇 |
2016年 | 3108篇 |
2015年 | 3545篇 |
2014年 | 4623篇 |
2013年 | 7265篇 |
2012年 | 9138篇 |
2011年 | 9508篇 |
2010年 | 6165篇 |
2009年 | 5581篇 |
2008年 | 8736篇 |
2007年 | 9583篇 |
2006年 | 9439篇 |
2005年 | 9013篇 |
2004年 | 8718篇 |
2003年 | 8203篇 |
2002年 | 7802篇 |
2001年 | 13349篇 |
2000年 | 13678篇 |
1999年 | 11444篇 |
1998年 | 3035篇 |
1997年 | 2793篇 |
1996年 | 2638篇 |
1995年 | 2552篇 |
1994年 | 2348篇 |
1992年 | 8333篇 |
1991年 | 8478篇 |
1990年 | 8278篇 |
1989年 | 8099篇 |
1988年 | 7324篇 |
1987年 | 7085篇 |
1986年 | 6735篇 |
1985年 | 6525篇 |
1984年 | 4771篇 |
1983年 | 4123篇 |
1982年 | 2475篇 |
1979年 | 4444篇 |
1978年 | 3239篇 |
1977年 | 2735篇 |
1976年 | 2506篇 |
1975年 | 2836篇 |
1974年 | 3358篇 |
1973年 | 3369篇 |
1972年 | 3122篇 |
1971年 | 2954篇 |
1970年 | 2841篇 |
1969年 | 2588篇 |
1968年 | 2542篇 |
1967年 | 2381篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
2.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
3.
4.
5.
6.
7.
8.
9.
Senem Maral Muradiye Acar Ozlem Sahin Balcik Eyyup Uctepe Omer Faruk Hatipoglu Derya Akdeniz Hatice Uludag Altun Ali Kosar Mehmet Gunduz Esra Gunduz 《Medicine》2015,94(16)
Chronic myeloproliferative disorders such as polycythemia vera (PV), essential thrombocytosis (ET), and idiopathic myelofibrosis arise from clonal proliferation of neoplastic stem cells in the bone marrow. Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that have potential to degrade all types of extracellular matrix (ECM) and also play a role in remodeling of the ECM. It is known that MMPs play a role in bone marrow remodeling.The primary goal of our study is to explore the relationship between chronic myeloproliferative diseases and some of MMP gene polymorphisms. The demonstration of a relationship will help to understand whether these polymorphisms may be a potential early diagnosis marker of the diseases.Patients were selected from outpatient clinics of Turgut Ozal University Hospital, Ankara, Turkey, between December 2010 and May 2011. Twenty-eight patients that previously diagnosed and followed-up with PV, 17 with secondary polycythemia (SP), and 12 with ET were enrolled in the study, along with a control group of 22 healthy people.DNA was isolated from peripheral blood. Using polymerase chain reaction–restriction fragment length polymorphism method, MMP2 and MMP9 gene polymorphisms were analyzed with agarose gel electrophoresis. There was a statistically significant difference between the study groups and the control group in terms of Gln279Arg polymorphisms rates of MMP9. The highest MMP9 Gln279Arg polymorphism rate was observed in the ET group. But nobody from the control group had polymorphic MMP9. There was no statistically significant difference between the groups in terms of MMP2-735 C > T polymorphism rates.In conclusion, MMP9 gene Gln279Arg polymorphism was associated with ET, SP, and PV diseases. Hence, we believe that these gene polymorphisms may play a role in the mechanism of bone marrow fibrosis and may be a factor that increases the risk of thrombosis. Illumination of the molecular basis of the relationship between MMP-thrombosis and MMP-fibrosis provides a better understanding of the pathophysiology of PV and ET diseases and will allow new approaches to diagnosis and treatment. 相似文献
10.
Loss‐of‐function mutations in the gene encoding filaggrin underlie a Japanese family with food‐dependent exercise‐induced anaphylaxis
下载免费PDF全文
![点击此处可从《Journal of the European Academy of Dermatology and Venereology》网站下载免费的PDF全文](/ch/ext_images/free.gif)